Search Videos and More
Kidney Cancer Research at ESMO
Dana-Farber's Toni Choueiri, MD, provides insight on KEYNOTE-564 trial in kidney cancer highlighted at ESMO 2021.Benefit of Immunotherapy Combination for Patients with Advanced Melanoma Extends to Subsequent Treatment, Study Finds
A combination of two immunotherapy drugs, already shown to be more effective in patients with advanced melanoma than one of the drugs alone, also prolongs the benefit to patients who receive subsequent therapies, a clinical trial led by Dana-Farber Cancer Institute investigators indicates. The findings will be presented today at the 2021 Congress of the European Society of Medical Oncology (ESMO).Antibody-Drug Conjugate Shows Impressive Activity in Patients with Non-Small Cell Lung Cancer with Mutation in HER2 Gene
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.Researchers Set Sights on New Ovarian Cancer Treatment Strategies
Despite breakthrough treatments for high-grade serous ovarian cancer, about 80 percent of patients relapse within two years, often resistant to treatment. The good news is that Dana-Farber scientists are pursuing multiple avenues of research that very well may improve outcomes.Five Dana-Farber Cancer Institute Faculty Members are Inducted in the 2021 Giants of Cancer Care®
Five Dana-Farber Cancer Institute faculty members are inductees of the 2021 Giants of Cancer Care® program.New Research Initiative Launches for All Patients Ever Diagnosed with Colorectal Cancer
Count Me In, a nonprofit cancer research initiative, is inviting all patients across the United States and Canada who have ever been diagnosed with colorectal cancer to participate in research and help drive new discoveries related to this disease.Dosing Strategies Help Personalize Care in HER2+ Breast Cancer
Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.Triplet Therapy Shows Promise in Phase 2 Study in Chronic Lymphocytic Leukemia
Dana-Farber researchers find that combining a BCL-2 inhibitor with two other targeted agents is active in previously untreated CLL patients.Dana-Farber Research Publication, 9.1.2021
Mantle Cell Lymphoma Clinical Trial
Targeted combination therapy for mantle cell lymphoma with minimal residual disease assessment.Personalized Cancer Vaccine Helps Patient
Richard Boylan speaks out about his experience with a personalized kidney cancer vaccine, saying he's 'extraordinarily lucky.' He's part of a clinical trial at Dana-Farber Cancer Institute. His doctor, David Braun, MD, PhD, is one of the scientists leading the research.Study Sounds Note of Caution on Effectiveness of COVID-19 Vaccines for Patients with Lymphoid Malignancies
Patients with lymphoma or other lymphoid cancers should continue to take steps to protect themselves from COVID-19 even if they have been vaccinated against the disease, a new study led by investigators at Dana-Farber Cancer Institute reports.